文献速递前列腺癌

多中心评估MRI靶向前列腺穿刺经会阴途径的性能指标

Multi-Institutional Assessment of Performance Metrics for MRI-Targeted Transperineal Prostate Biopsy.
PubMed 文献 · J Urol · 2026-06-30

该研究在5家机构的前瞻性数据库中纳入1587例同时接受MRI靶向和系统经会阴前列腺穿刺的患者,评估可操作信息指标(AIM)和减少指标(ReM)。总体AIM为27.4%,ReM为83.3%;若省略系统穿刺,最多17%的临床显著癌会被漏诊。结论认为AIM和ReM可用于经会阴穿刺场景,但单独靶向穿刺需个体化评估风险耐受性。

要点

  • 经会阴穿刺队列中AIM为27.4%,ReM为83.3%。
  • 各PI-RADS评分和既往穿刺状态亚组AIM>25%、ReM>80%。
  • 省略系统穿刺可能漏诊最多17%的临床显著癌。

核心结论

  • AIM和ReM可应用于经会阴穿刺场景,评估MRI靶向前列腺穿刺的 deliverables。
  • 靶向穿刺在27%的男性中提供可操作信息,但省略系统穿刺最多漏诊17%的临床显著癌。
  • 若采用仅靶向穿刺策略,需个体化评估患者风险耐受性。

研究设计与样本

  • 多机构回顾性队列研究,纳入5家机构前瞻性前列腺癌数据库中同时接受MRI靶向和系统经会阴穿刺的所有患者。
  • 共分析1587例经会阴穿刺,其中797例(50%)为≥Grade Group 2前列腺癌。

主要发现

  • 总体队列AIM为27.4%,ReM为83.3%。
  • 按PI-RADS评分和既往穿刺状态分层,所有亚组AIM>25%、ReM>80%。
  • 多变量logistic回归显示,PI-RADS 5病变和在机构D进行的穿刺预测系统穿刺升级率更高,既往阴性穿刺患者系统升级可能性降低。

关键数值与推荐

  • AIM定义为靶向穿刺较单独系统穿刺检测到更高Grade Group的男性百分比。
  • ReM定义为可省略系统穿刺的男性比例。

临床怎么用

  • 在经会阴穿刺中可用AIM和ReM量化MRI靶向穿刺的获益与系统穿刺的省略空间。
  • 考虑仅靶向穿刺时,应结合患者风险耐受性个体化决策,因可能漏诊部分临床显著癌。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Evidence supports obtaining MRI before prostate biopsy. Deliverables of MRI include improving prostate cancer detection through targeting of MRI lesions and reducing the total number of biopsies by eliminating the need for nontargeted biopsy. The actionable intelligence metric (AIM) and reduction metric (ReM) have been proposed to quantify these 2 deliverables; however, this work was performed in the transrectal biopsy setting. To assess generalizability, we examined AIM and ReM in a large, multi-institutional cohort of men undergoing transperineal biopsy. MATERIALS AND METHODS: All patients undergoing concurrent MRI-targeted and systematic transperineal biopsy and maintained in prospective prostate cancer databases across 5 institutions were included. AIM is the percent of men in whom targeted biopsy detected a higher Grade Group compared with systematic biopsy alone. ReM is the proportion of men in whom systematic biopsy may be omitted. In addition to total cohort evaluations of AIM and ReM, subgroup analyses and multivariable logistic regression were performed. RESULTS: In total, 1587 transperineal biopsies were analyzed; 797 (50%) had ≥ Grade Group 2 prostate cancer. AIM in the overall cohort was 27.4%, and ReM was 83.3%. When stratified by Prostate Imaging Reporting and Data System score and prior biopsy status, AIM and ReM were > 25% and > 80%, respectively, across all subgroups. On multivariable logistic regression, Prostate Imaging Reporting and Data System 5 lesions and biopsies performed at institution D were predictive of higher rates of upgrading on systematic biopsy, while patients with a prior negative biopsy had a decreased likelihood of systematic upgrading. CONCLUSIONS: AIM and ReM can be applied in the transperineal setting to assess deliverables of MRI-targeted prostate biopsy. Targeted biopsies provided actionable information in 27% of men, while up to 17% of clinically significant cancer would be missed if systematic biopsy were omitted. Individualized assessment of patient risk tolerance is necessary if a targeted biopsy-alone approach is to be adopted.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Buller DM, Dubovic V, Martin WE, et al. Multi-Institutional Assessment of Performance Metrics for MRI-Targeted Transperineal Prostate Biopsy. J Urol. 2026. PMID: 42378344. doi:10.1097/JU.0000000000005196

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。